Serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae associated with invasive pneumococcal disease among adults in Japan

• Main Authors: Katsunori Yanagihara, Kosuke Kosai, Hiroshige Mikamo, Hiroshi Mukae, Yoshio Takesue, Machiko Abe, Kazuko Taniguchi, Tanaz Petigara, Mitsuo Kaku
• Format: Article
• Language: English
• Published: Elsevier 2021-01-01
• Series: International Journal of Infectious Diseases
• Subjects: Invasive pneumococcal disease; Antimicrobial susceptibility; Japan; Pneumococcal vaccines; Streptococcus pneumonia; Serotyping
• Online Access: http://www.sciencedirect.com/science/article/pii/S1201971220322220

Objectives: This study evaluated the serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae isolates from adults (aged ≥20 years) with invasive pneumococcal disease (IPD) in Japan. Methods: This prospective observational study was conducted in 49 participating Japanese hospitals. S. pneumoniae isolates were serotyped and tested for antimicrobial susceptibility at a central laboratory. Information regarding patient characteristics, underlying disease, IPD clinical syndromes, and treatment was collected through medical chart review. Results: The final analysis included 177 patients enrolled from 45 hospitals between September 2016 and April 2018 (bacteraemic pneumonia, 110; bacteraemia without identified focus, 29; meningitis, 19). Most patients (70.1%) were aged ≥65 years and most had underlying disease (79.1%). The proportion of isolates from serotypes contained in the pneumococcal polysaccharide vaccine (PPV) 23 was 61.0%, while those in the pneumococcal conjugate vaccine (PCV) 7 and PCV13 were 2.8% and 28.2%, respectively. Non-vaccine serotypes accounted for 37.9% of all isolates and 50.8% of isolates from immunosuppressed patients. Serotype 12F was the most common vaccine serotype, followed by serotype 3. Conclusions: The continued disease burden of IPD in adults in Japan warrants improved vaccination rates and development of next-generation vaccines that include serotypes not currently covered. Clinical trial registration: Clinical trial summary registration number 160,822,918,146; JapicCTI-163352.